Frontlight ResearchEarly access
CompletedPhase 3
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
Key facts
- Who runs it
- BioTissue Holdings, Inc
- Where
- Boston, Circleville, Dallas, DeLand, Delray Beach, Guntersville, Houston, Los Angeles, Mather, O'Fallon, Palmdale, Reno, Tucson, Westwood, and Whittier, United StatesSee the 16 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 106 people enrolled
- Started
- 20 Nov 2020
- Ended
- 24 Mar 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- TTAX01
- Standard care
- Record updated
- 1 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (28)Hide the full registry criteria
Who can take part
- The subject has signed the informed consent form
- The subject is male or female, at least 18 years of age inclusive at the date of Screening
- The subject has confirmed diagnosis of Type I or Type II diabetes
- The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
- The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
- The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
- The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
- The subject has an Ankle-Brachial Index ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
- The subject is under the care of a physician for the management of Diabetes Mellitus
- The subject is willing to return for all mandatory visits as defined in the protocol
- The subject is willing to follow the instructions of the trial Investigator
Who cannot take part
- The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
- The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
- The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
- The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine contraceptive device; or surgical sterilization of partner)
- The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
- The subject's index ulcer is primarily located on the dorsal surface of the foot
- The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
- The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
- The subject has an allergy to primary or secondary dressing materials used in this trial
- The subject has an allergy to glycerol
- The subject's index ulcer is over an acute Charcot deformity
- Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
- The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% †
- The subject has a contralateral major amputation of the lower extremity
- The subject is pregnant
- The subject is a nursing mother
- The subject is unable to sustain off-loading as defined by the protocol
Where in United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Cutting Edge Research, LLCCircleville, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Midland Florida Clinical Research CenterDeLand, United States
- Delray Physician Care CenterDelray Beach, United States
- Lakeview Clinical ResearchGuntersville, United States
- Advantage Foot Care of HoustonHouston, United States
- Biolife Genetics ResearchHouston, United States
- Clemente Clinical ResearchLos Angeles, United States
- VA Northern California Health Care SystemMather, United States
- Gateway Clinical Trials, LLCO'Fallon, United States
- CureCentricPalmdale, United States
- Reno Orthopedic ClinicReno, United States
- Banner University Medical Center - TucsonTucson, United States
- Curalta Foot and AnkleWestwood, United States
- PIH HealthWhittier, United States
About the trial
What the trial wants to find out
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.
The 2 groups in the trial
- TTAX01Treatment being tested
TTAX01 plus standard of care
Treatment: TTAX01 and Standard care
- ControlOther group
Standard care alone
Treatment: Standard care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
- Record updated
- 1 April 2025